

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Simcere Pharmaceutical Group Limited**

**先聲藥業集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 2096)**

### **VOLUNTARY ANNOUNCEMENT LATEST DEVELOPMENTS OF RADEMIKIBART**

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

Reference is made to the announcement of the Company on July 8, 2025, the Group’s New Drug Application (“**NDA**”) for Rademikibart, an innovative drug jointly developed by the Group and Connect Biopharma Hong Kong Limited, has been accepted by the National Medical Products Administration (NMPA) for the treatment of atopic dermatitis in adults and adolescents.

#### **LATEST DEVELOPMENTS OF RADEMIKIBART**

As part of the strategic optimization of the product’s overall commercialization plan, the Company has voluntarily withdrawn the NDA for Rademikibart and expects to resubmit the NDA within this month. The Company will closely communicate with regulatory authorities to seek approval for market launch as soon as possible.

The phase 3 clinical studies showed that Rademikibart not only acts rapidly but also demonstrates significant cumulative benefits with continued treatment, showing potential for greater effectiveness compared to similar class of products.

At week 16, the response rates for EASI-75, EASI-90 and IGA 0/1 in the Rademikibart group reached 74.2%, 43.0% and 47.7% ( $p < 0.0001$ ), respectively, indicating clear clinical benefits in early treatment.

By Week 52, the response rates for EASI-75, EASI-90 and IGA 0/1 had increased to 96.6%, 85.3% and 87.1%, respectively, demonstrating a significant advantage in deep remission with long-term treatment.

## **ABOUT RADEMIKIBART**

Rademikibart is a fully human monoclonal antibody targeting IL-4R  $\alpha$ , a common subunit of IL-4 receptor and IL-13 receptor. By binding with IL-4R  $\alpha$ , Rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the Th2 inflammatory pathway, thus achieving the goal of treating Th2-related inflammatory diseases such as atopic dermatitis and asthma.

## **ABOUT THE GROUP**

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board  
**Sincere Pharmaceutical Group Limited**  
**Mr. Ren Jinsheng**  
*Chairman and Executive Director*

Hong Kong, April 22, 2026

*As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.*